药效团
雄激素受体
LNCaP公司
化学
IC50型
二氢睾酮
雄激素受体拮抗剂
配体(生物化学)
立体化学
对接(动物)
雄激素
组合化学
受体
前列腺癌
生物化学
癌症
体外
医学
内科学
激素
护理部
作者
Ayumi Yamada,Shinya Fujii,Shuichi Mori,Hiroyuki Kagechika
摘要
We report the design and synthesis of novel 4-(4-benzoylaminophenoxy)phenol derivatives that bind to the androgen receptor (AR) ligand-binding domain and exhibit potent androgen-antagonistic activity. Compound 22 is one of the most potent of these derivatives, inhibiting the dihydrotestosterone-promoted growth of SC-3 cell line bearing wild-type AR (IC50 0.75 μM), LNCaP cell line bearing T877A-mutated AR (IC50 0.043 μM), and 22Rv1 cell line bearing H874Y-mutated AR (IC50 0.22 μM). Structure-activity relationship studies confirmed that the pharmacophore of these novel AR antagonists is distinct from the nitro- or cyano-substituted anilide substructure of other nonsteroidal AR antagonists. This novel pharmacophore is expected to provide a basis for designing new antiprostate cancer agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI